Does DEFERASIROX Cause Second primary malignancy? 16 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Second primary malignancy have been filed in association with DEFERASIROX (Deferasirox). This represents 0.1% of all adverse event reports for DEFERASIROX.
16
Reports of Second primary malignancy with DEFERASIROX
0.1%
of all DEFERASIROX reports
9
Deaths
12
Hospitalizations
How Dangerous Is Second primary malignancy From DEFERASIROX?
Of the 16 reports, 9 (56.3%) resulted in death, 12 (75.0%) required hospitalization, and 5 (31.3%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DEFERASIROX. However, 16 reports have been filed with the FAERS database.
What Other Side Effects Does DEFERASIROX Cause?
Death (1,583)
Diarrhoea (993)
Serum ferritin increased (732)
Haemoglobin decreased (615)
Pyrexia (607)
Malaise (605)
Nausea (603)
Sickle cell anaemia with crisis (570)
Vomiting (520)
Pneumonia (494)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which DEFERASIROX Alternatives Have Lower Second primary malignancy Risk?
DEFERASIROX vs DEFERIPRONE
DEFERASIROX vs DEFEROXAMINE
DEFERASIROX vs DEFIBROTIDE
DEFERASIROX vs DEFLAZACORT
DEFERASIROX vs DEGARELIX